Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Dan Zhao 1,2, Haiqing Li 3,4, Isa Mambetsari 1, Tamara Mirzapoia 1, Chen Chen 4, Jeremy Fricke 1, Prakash Kulkarni 1, Victoria Villaflor 1, Leonidas Arvanitis 5, Stanley Hamilton 5, Michelle Afkhami 5, Raju Pillai 5, Brian Armstrong 6, Loretta Erhunmwunsee 7, Erminia Massarelli 1, Martin Sattler 8,9, Arya Amini 10 and Ravi Salgia 1,4,7

Abstract: Background: The molecular and clinical features of KRAS-mutated lung cancer patients treated with immunotherapy have yet to be well characterized, and little information is known about resistance in these patients. The goal of this study is to better understand the survival results of KRAS-mutated patients who undergo immunotherapy treatment. For this effort, we have included 87 patients with NSCLC who received immunotherapy at the City of Hope, and we found that, among 87 patients, 32 had a KRAS G12C mutation (36.8%), 19 had G12V (21.9%), 18 had G12D (20.7%), 6 had G12A (6.9%), 3 had G12R (3.45%), and 10 had amplification (11.49%) and other uncommon mutations.

Question: Do KRAS-mutated patients with different subtypes and comutations have different clinical responses and overall survival (OS) to checkpoint inhibitors? Study Design and Methods: 87 patients with NSCLC who received immunotherapy at the City of Hope were included. Tumor genomic alterations were extracted from the clinical data with next-generation sequencing using various platforms. Demographic, clinical, molecular, and pathological information was collected with the approval of the institutional review board of the City of Hope. OS was calculated if it was available at the study time point, and responses were determined according to the RECIST v1.1. Results: Among 87 patients, 32 had a KRAS G12C mutation (36.8%), 19 had G12V (21.9%), 18 had G12D (20.7%), 6 had G12A (6.9%), 3 had G12R (3.45%), and 10 had amplification (11.49%) and other uncommon mutations. G12D patients were found to respond differently compared to other KRAS-mutated patients. The OS with other KRAS mutations was not statistically significant, including STK11 and KEAP1. KRAS mutation subtypes such as G12D and comutations such as CDKN2/A and MET may modulate the immunotherapy responses and outcome in lung cancer.

Check for updates

Citation: Zhao, D.; Li, H.; Mambetsari, I.; Mirzapoia, T.; Chen, C.; Fricke, J.; Kulkarni, P.; Villaflor, V.; Arvanitis, L.; Hamilton, S.; et al. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers 2022, 14, 4933. https://doi.org/10.3390/cancers14194933

Academic Editor: Margarete Odenthal

Received: 17 August 2022
Accepted: 3 October 2022
Published: 8 October 2022

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
who had G12D mutation and the patients who had other KRAS mutations (HR (95% CI) = 0.53 (0.21–1.36), p = 0.185). The median OS was significantly worse with KRAS comutation CDKN2A/B loss (4.2 vs. 16.9 months, HR = 3.07 (1.09–8.69), p < 0.05) and MET (3.4 vs. 17 months, HR = 3.80 (1.44–10.05), p < 0.01), which were included for the multivariate analysis. The OS with other KRAS comutations was not statistically significant, including STK11 and KEAP1. Conclusion: KRAS mutation subtypes such as G12D and comutations such as CDKN2/A and MET may modulate the immunotherapy responses and outcomes in lung cancer.

**Keywords:** KRAS; immune checkpoint inhibitors; next-generation sequencing; precision medicine

---

1. Introduction

Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogenic driver in solid tumors including lung cancer and was associated with a worse prognosis and resistance to chemotherapy and anti-epidermal growth factor receptor (EGFR) treatment [1,2]. Targeting KRAS has been challenging for decades due to the lack of known drug-binding pockets. Recently, allosteric KRAS\textsuperscript{G12C} mutant-specific inhibitors that covalent bind to the mutant cysteine beneath the switch-II region, which locks it at the inactive GDP bound form, were discovered [3,4]. Early phase clinical trials of the KRAS\textsuperscript{G12C} inhibitors including sotorasib (AMG510) and adagrasib (MRTX849) in solid tumors were encouraging, and Sotorasib was FDA-approved for previously treated KRAS\textsuperscript{G12C}-mutated non-small cell lung cancer (NSCLC) [5–11]. The first-in-human phase 1 trial of Sotorasib showed a disease control rate of 90% (5 partial responses, 4 stable diseases) in the 10 NSCLC patients, and the phase 2 trial reported a 37.1% response rate and an 80.6% disease control rate with a median duration of response of 11.1 months in previously treated KRAS\textsuperscript{G12C}-mutated advanced lung cancer patients [7,12]. Interestingly, treatment with the KRAS\textsuperscript{G12C} inhibitor resulted in a pro-inflammatory tumor microenvironment and synergistic effects with immunotherapy with increased T cells, macrophages, and dendritic cells infiltration [5]. The RAS/MAPK pathway is essential for T cell development, proliferation, differentiation, and function [13]. Challenges for targeting KRAS include the limited response rate and the short duration of the response to KRAS inhibitors, which prompted the early clinical investigation of combining KRAS-targeted therapy with immunotherapy including immune checkpoint inhibitors (ICIs) in KRAS-mutated patients [14].

Immune checkpoint inhibitors (ICIs) are currently used as monotherapy or combination therapy in the frontline and subsequent lines for metastatic non-small cell lung cancer (NSCLC) [15–19]. Furthermore, ICIs before or after surgery showed efficacy in patients with resectable disease in neoadjuvant and adjuvant settings, highlighting the potential of ICIs to improve outcomes in this patient group [20,21]. The response rates in lung cancer to ICIs are approximately 20% for monotherapy and 40% for combination therapy, but eventually, most patients have progression of the disease, and overcoming resistance is an unmet need [22,23]. Mutated KRAS causes phenotypic switching of naïve T cells to immune suppressive Treg-like cells, possibly with metabolic changes of less utilization of glucose-6-phosphate [24]. Targeting KRAS could potentially overcome the primary and acquired resistance to immunotherapy. Multiple trials are currently ongoing, combining KRAS\textsuperscript{G12C} inhibitors with ICIs in cancer patients.

KRAS-mutated cancers are heterogeneous, and genomic comutations, MET amplification, metabolic reprogramming, and EGFR signaling represent some possible mechanisms of resistance to the KRAS\textsuperscript{G12C} inhibitors and immunotherapy [6,25–29]. The predictive role of KRAS mutation in checkpoint inhibitors’ treatment outcomes is inconsistent with their genetic heterogeneity and complexity [30,31]. KRAS-mutated patients benefit from immunotherapy, and KRAS mutations were not found to be different in the overall population compared with patients who had durable clinical benefits with checkpoint inhibitors [32–36]. The comutations with KRAS were not reported to be the primary drivers of molecular and immuno-
logical differences in KRAS-mutant lung adenocarcinomas, while specific KRAS mutations (KRAS$^{G12C}$, KRAS$^{G12V}$, KRAS$^{G12D}$, and others) did not have a consistent pattern [37]. The comutation of STK11/LKB1 was reported to have higher KEAP1 mutational inactivation and fewer immune cells, while the comutation of TP53 was associated with higher inflammatory markers and longer relapsed free survival in KRAS-mutated lung cancer [37]. In an in vitro study, the genomic loss of KEAP1 represented a mechanism of resistance to the KRAS$^{G12C}$ inhibitor adagrasib (MRTX849) [6]. The comutation of STK11/LKB1 and the comutation of KEAP1/NFE2L2 were identified as genomic drivers for primary resistance to immune checkpoint inhibitors in KRAS-mutated lung adenocarcinoma [38,39].

With the development of KRAS inhibitors and combination strategies of KRAS inhibition with immunotherapy and other targeted therapies, there is an unmet need of characterizing the clinical and molecular features of KRAS-mutated lung cancer patients treated with immunotherapy to facilitate pre-clinical investigations and clinical development. Clinical and molecular profiling is needed for the selection of patients, and the identification of novel therapeutic targets and strategies to improve the response rates and the duration of responses to treatments including ICIs and KRAS inhibition in KRAS-mutated patients. In this study, we analyzed the clinical and molecular characteristics of 87 lung cancer patients with mutated KRAS who had received monotherapy ICIs to identify the associations with the clinical outcomes of responses and overall survival (OS).

2. Patients & Methods

2.1. Patients

Patients ($n = 87$) with NSCLC at the City of Hope National Medical Center who received ICIs (pembrolizumab, nivolumab, atezolizumab, or durvalumab) were identified retrospectively in different settings, with the cutoff date of 11 August 2018, including standard of care, compassionate use, and clinical trials. The information on tumor genomic alterations (GAs) was extracted from the available clinical data, including mutations in KRAS, EGFR, TP53, and PD-L1. The testing using various next-generation sequencing (NGS) platforms included FoundationOne (Foundation Medicine, Cambridge, MA, USA), Caris (Caris Life Science, Phoenix, AZ, USA), Paradigm (Paradigm Diagnostics, Phoenix, AZ, USA), Guardant360 (Guardant, Redwood City, CA, USA), NeoGenomics (NeoGenomics Laboratories, Fort Myers, FL, USA), or targeted gene sequencing panels at the City of Hope. The Tumor Proportion Score (TPS) was used to quantify PD-L1 (22C3) expression by IHC. Negative PD-L1 is defined as <1% of viable tumor cells showing membranous staining.

The City of Hope institutional review board approved the collection of demographic, clinical, and pathological information. The informed consent was waived, as per the IRB guidelines for retrospective studies on clinical and molecular information. Overall survival (OS, from the start of the ICIs) was calculated if it was available at the study time point. Responses were determined by clinical and radiological evaluation according to the RECIST v1.1 criteria [40].

2.2. Statistical Analysis

The OS was defined as the overall survival from the start of ICI treatment until death. In this study, the Hazard Ratios (HR) are estimated using overall survival (OS). The univariate COX proportional hazards model was used to test the association of clinical and molecular features with OS independently first. Based on the univariate analysis result, clinically and biologically relevant features with statistical significance (cutoff $p$-value < 0.05) were selected for the multivariate COX proportional hazards model analysis. PD-L1 expression was categorized as negative (<1%), 1%–<50%, and ≥50%. Overall survival (OS) was estimated using the Kaplan–Meier method. The difference in survival curves was tested using the Log-rank test. GraphPad Prism 8 (GraphPad Software) and R ver. 3.6.2 were used for the statistical analyses and data visualization. All tests were two-sided, and statistical significance was identified with a $p$-value < 0.05.
3. Results

3.1. Patient Characteristics

The baseline characteristics of 87 KRAS-mutated patients were summarized based on their age, sex, smoking status, histology, TP53 status, and PD-L1 expression (Table 1). The median age was 68.5 years (range 49–89). A total of 38 (43.7%) patients were ≥70 years old and 49 (56.3%) were <70 years old at the beginning of the ICI treatment. A total of 42 (48.3%) were female and 45 (51.7%) were male; 16 (18.4%) were never smokers, 61 (70.1%) were former smokers, and 10 (11.5%) were current smokers. The histology was predominantly adenocarcinoma (n = 83, 95.4%), with two cases of squamous cell lung cancer (2.3%) and two (2.3%) cases of other types (one poorly differentiated large cell lung cancer and one poorly differentiated carcinoma). PD-L1 was tested in 66 patients: 21 (32.3%) were negative (<1%), 31 (47.7%) were ≥50%, and 13 (20%) were between 1% and <50%. TP53 was tested in 79 patients—38 (48.1%) positive and 41 (51.9%) negative patients. A total of 84 patients (96%) had stage IV disease, while 2 patients had Stage IIIIB disease and 1 patient had stage IIIA disease at the time of diagnosis.

Table 1. Baseline patient characteristics (n = 87).

| Characteristics                | No. of Patients (n = 87) | CR/PR (n = 42) | PD (n = 36) | p-Value b |
|--------------------------------|--------------------------|----------------|-------------|-----------|
| Age, years, at ICIs            |                          |                |             |           |
| <70                            | 49 (56.3%)               | 24 (57%)       | 20 (56%)    | 1         |
| ≥70                            | 38 (43.7%)               | 18 (43%)       | 16 (44%)    |           |
| Sex                            |                          |                |             |           |
| Women                          | 42 (48.3%)               | 20 (47%)       | 18 (50%)    | 0.82      |
| Men                            | 45 (51.7%)               | 22 (53%)       | 18 (50%)    |           |
| Smoking status                 |                          |                |             |           |
| Current                        | 10 (11.5%)               | 7 (17%)        | 3 (8%)      | 0.33      |
| Former                         | 61 (70.1%)               | 29 (69%)       | 24 (67%)    |           |
| Never                          | 16 (18.4%)               | 6 (14%)        | 9 (25%)     |           |
| Histology                      |                          |                |             |           |
| Lung adenocarcinoma            | 83 (95.4%)               | 40 (95.2%)     | 34 (94%)    | 0.99      |
| Lung squamous                  | 2 (2.3%)                 | 1 (2.4%)       | 1 (3%)      |           |
| Others a                       | 2 (2.3%)                 | 1 (2.4%)       | 1 (3%)      |           |
| TP53                           |                          |                |             |           |
| Positive                       | 38 (48.1%)               | 17 (44%)       | 17 (55%)    | 0.49      |
| Negative                       | 41 (51.9%)               | 22 (56%)       | 14 (45%)    |           |
| Total tested                   | 79                       | 39             | 31          |           |
| PD-L1                          |                          |                |             |           |
| Negative                       | 21 (32.3%)               | 11 (32%)       | 8 (30%)     | 0.001     |
| 1–50%                          | 13 (20%)                 | 1 (6%)         | 11 (40%)    |           |
| ≥50%                           | 31 (47.7%)               | 21 (62%)       | 8 (30%)     |           |
| Total tested                   | 65                       | 33             | 27          |           |

a Others included one poorly differentiated large cell carcinoma and one poorly differentiated carcinoma. b p-values derived from Fisher’s exact tests. c % Based on total tested patients.

3.2. KRAS Mutation Subtypes with Responses and OS

Among 87 patients, 32 of them had KRASG12C (36.8%), 19 had KRASG12V (21.9%), 18 had KRASG12D (20.7%), 6 had KRASG12A (6.9%), 3 had KRASG12R (3.45%), 10 had KRAS amplification (11.49%), 1 had KRASG12S (1.1%), 1 had KRASG13D (1.15%), 1 had KRASG13R (1.1%), 2 had KRASQ61L (2.3%), 2 had KRASQ61H (2.3%), 1 had KRASG117N (1.15%), and 1 had all three of KRASG12D, KRASG12V, and KRASG12R (1.15%) (Figure 1).

G12D has a statistically significant Odds Ratio (OR) between patients that had responses and progression of the disease (OR (95% CI) = 0.31 (0.09–0.95), p < 0.05) and 5 KRAS G12D-mutated patients who had responses and 11 KRAS G12D-mutated patients who had progression of the disease. In the univariate analysis with OS, there was a trend of a
better OS in KRAS G12D-mutated patients, with no statistically significant difference in OS between patients who had G12D mutations and patients who had other KRAS mutations (Table 2, HR (95% CI) = 0.53 (0.21–1.36), p = 0.185). However, in the multivariate analysis, G12D-mutated patients had a longer OS compared with patients who had other KRAS genomic alterations (Table 3, HR (95% CI) = 0.09 (0.01–0.68), p = 0.02). Patients who had KRAS G12V mutations had a trend of a worse OS that was not statistically significant by either univariate (Table 2, HR (95% CI) = 1.94 (0.95–3.96), p = 0.068) or multivariate analysis (Table 3, HR (95% CI) = 4.13 (0.98–17.50), p = 0.053). For the other KRAS mutation subtypes, we did not find statistical significance with OS nor with responses.

Figure 1. KRAS mutation subtype characteristics by response (n = 87).

Table 2. KRAS mutation subtypes with responses and OS (n = 87).

| KRAS GAs | No. (n = 87) | CR/PR (n = 42) | PD (n = 36) | OR (95% CI) | OR p-Value | OS Association HR (95% CI) | HR p-Value |
|----------|--------------|----------------|-------------|-------------|------------|-----------------------------|------------|
| G12C     | 32 (36.8%)   | 16             | 15          | 0.86 (0.35–2.15) | 0.748      | 1.00 (0.52–1.93)             | 0.997      |
| G12V     | 19 (21.9%)   | 9              | 7           | 1.13 (0.37–3.53) | 0.829      | 1.94 (0.95–3.96)             | 0.068      |
| G12D     | 18 (20.7%)   | 5              | 11          | 0.31 (0.09–0.95)  | 0.048 *    | 0.53 (0.21–1.36)             | 0.185      |
| G12A     | 6 (6.9%)     | 3              | 2           | 1.31 (0.21–10.37) | 0.776      | 1.09 (0.38–3.09)             | 0.875      |
| G12R     | 3 (3.5%)     | 1              | 1           | 0.85 (0.03–22.12) | 0.912      | 0 (0–inf)                   | 0.997      |
| Q61H     | 2 (2.3%)     | 2              | 0           | NA           | 0.992      | 0.34 (0.04–2.67)             | 0.306      |
| Q61L a   | 2 (2.3%)     | 0              | 1           | 0.991        | 7.75 (1.71–35) | 0.008 **                    |            |
| G12S     | 1 (1.1%)     | 0              | 0           | NA           | 0.992      | 0 (0–inf)                   | 0.997      |
| G13D     | 1 (1.1%)     | 0              | 0           | NA           | 0.992      | 0 (0–inf)                   | 0.996      |
| G13R     | 1 (1.1%)     | 0              | 1           | NA           | 0.991      | 0 (0–inf)                   | 0.997      |
| K117N    | 1 (1.1%)     | 1              | 0           | NA           | 0.992      | 2.41 (0.33–17.82)            | 0.338      |
| KRAS a amp | 10 (11.5%)   | 6              | 3           | 1.83 (0.45–9.24) | 0.417      | 0.59 (0.18–1.92)             | 0.381      |
| Other b  | 1 (1.1%)     | 0              | 1           | NA           | 0.991      | 0 (0–inf)                   | 0.997      |

* One patient had an unknown response status. * One patient had G12D, G12V, and G12R. * p < 0.05, ** p < 0.01.
Table 3. Multivariate analysis for OS.

| Risk Factors                        | HR (95% CI) | p-Values 1 |
|-------------------------------------|-------------|------------|
| PD-L1                               |             |            |
| Negative or less than 50%           | Reference   |            |
| 50% above                           | 0.12 (0.03–0.57) | 0.007 **   |
| CDKN2A/B Loss                       |             |            |
| Negative                            | Reference   |            |
| Positive                            | 9.44 (1.90–46.93) | 0.006 **   |
| MET Mutation                        |             |            |
| Negative                            | Reference   |            |
| Positive                            | 3.46 (0.55–21.91) | 0.186      |
| KRAS G12V Mutation                  |             |            |
| Negative                            | Reference   |            |
| Positive                            | 4.13 (0.98–17.50) | 0.053      |
| KRAS G12D Mutation                  |             |            |
| Negative                            | Reference   |            |
| Positive                            | 0.09 (0.01–0.68) | 0.02 *     |
| Age                                 |             |            |
| <70                                 | Reference   |            |
| >=70                                | 1.26 (0.35–5.25) | 0.66       |
| Sex                                 |             |            |
| Female                              | Reference   |            |
| Male                                | 1.53 (0.45–5.14) | 0.49       |
| Smoking Status                      |             |            |
| Never                               | Reference   |            |
| Current                             | 0.38 (0.04–3.25) | 0.38       |
| Former                              | 0.33 (0.07–1.47) | 0.15       |

1 Multivariate COX proportional hazards model for OS. * p < 0.05; ** p < 0.01.

3.3. KRAS Mutations and OS

The top detected GAs and the patient’s clinical information (Figure 2) were sorted by the detected positive rate of GAs among tested patients (the number of tested patients for each gene varied due to different gene panels in the testing platforms). TP53 (n = 38) ranked as the most frequently detected comutation with KRAS (87 patients), with a 48% positive rate in the 79 patients tested for TP53, followed by LRP1B (11/40, 28%), SPTA1 (9/34, 26%), ARID1B (9/35, 26%), SMARCA4 (11/43, 26%), MLL3 (9/37, 24%), STK11 (15/75, 20%), EPHA3 (7/37, 19%), KEAP1 (7/41, 17%), NXX2-1 (6/36, 17%), MLL (6/40, 15%), FAT1 (5/37, 14%), ATM (10/75, 13%), and NFI (5/40, 13%).

The results showed CDKN2A/B loss (6/49, 12%), TSC2 (6/52, 12%), TET2 (4/37, 11%), and ARID2 (4/38, 11%). Some KRAS-mutated patients had targetable genomic alterations (GA). A total of 9% of the patients were positive for MET genomic alteration (7/79), including two amplifications, one exon 14 deletion, one T1010I mutation, one D428G mutation, one A347T mutation (Variants of Unknown Significance, VUS), and one T948H mutation (VUS). GAs of the EGFR gene were found in 5% of the patients (4/85: 1 patient had E282K mutation, 1 patient had T790M and L858R mutation, and 2 patients had amplification). In total, 4% had ERBB2 mutation (3/78), including two patients who had amplification and one who had E645K mutation. A total of 3% of the patients had BRAF amplification (2/81), and 1% of patients (1/80) were positive for ALK.

The univariate COX analysis revealed a statistically significant (p < 0.05) association between OS and PD-L1 status. Patients with a PD-L1 level ≥50% showed a longer OS compared with PD-L1-negative patients (HR; 95% CI; p < 0.01). The median OS for PD-L1-negative patients is 7.1 months. The median OS for patients who had PD-L1 between 1% and 50% is 8.1 months. For patients who had PD-L1 ≥50%, the lower 95% CI of the median OS is 19 months (Figure 3A). The median OS was also significantly worse with KRAS comutation CDKN2A/B loss (4.2 vs. 16.9 months, HR = 3.07 (1.09–8.69), p < 0.05, Figure 3B) and MET (3.4 vs. 17 months, HR = 3.80 (1.44–10.05), p < 0.01, Figure 3C) which were included for the multivariate analysis. The association of OS with other KRAS comutations
was not statistically significant, including STK11 (HR = 1.13 (0.43–2.97), p = 0.812), KEAP1 (HR = 1.83 (0.51–6.54), p = 0.35), ARID1A (HR = 0.24 (0.03–1.80), p = 0.166), ATM (HR = 0.52 (0.16–1.72), p = 0.285), TSC2 (HR = 2.37 (0.66–8.46), p = 0.183), MYC (HR = 2.78 (0.91–8.43), p = 0.071), and others (Supplementary Table S1).

Figure 2. Oncoplot for KRAS common genetic co-occurring mutations (gray signifies that the gene was not tested) and their associations with response (odds ratio) and overall survival (hazard ratio).

Figure 3. KRAS mutations with overall survival (OS) and Hazard Ratio. (A) OS with PD-L1 status in all KRAS-mutated patients tested (n = 65). (B) OS with CDKN2A/B comutation status in all KRAS-mutated patients tested (n = 49). (C) OS with MET comutation status in all KRAS-mutated patients tested (n = 78). (D) KRAS mutations with Hazard Ratio.
In the multivariate COX proportional hazards model analysis, we included PD-L1 status, genomic alterations (CDKN2A/B and MET) associated with OS by univariate analysis, and KRAS subtypes (G12D and G12V). We also included the demographic factors including gender, age group, and smoking status in the multivariate model. The multivariate analysis showed that PD-L1 remains statistically significant (HR (95% CI) = 0.12 (0.03–0.57), \( p < 0.01 \)), as well as CDKN2A/B loss (HR (95% CI) = 9.44 (1.90–46.93), \( p = 0.006 \)). The association of a worse OS with the KRAS comutation of MET (HR = 3.80 (1.44–10.05); \( p < 0.01 \); Figure 3C) was not retained in the multivariate COX proportional hazards model (Table 3, HR = 3.46 (0.55–21.91), \( p = 0.186 \)). No statistical significance was found for age, gender, and smoking status with OS in the univariate analysis and multivariate analysis.

4. Discussion

In this study, we analyzed the clinical and molecular features of 87 KRAS-mutated lung cancer patients treated with ICIs at the City of Hope. We characterized the KRAS mutation subtypes and comutations with responses to ICIs and survival outcomes. As expected, the higher PD-L1 expression level is associated with a longer survival. The median OS for negative PD-L1 expression (<1%), 1%–<50%, and ≥50% is 7.1 months, 8.1 months, and more than 19 months (\( p < 0.01 \)).

KRAS comutation with CDKN2A/B loss was associated with a worse OS (median 4.2 vs. 16.9 months, HR = 3.07 (1.09–8.69), \( p < 0.05 \), Figure 3B). This is consistent with our previous findings of the least favorable outcome of lung cancer patients harboring CDKN2A/B loss treated with ICIs in another cohort with both KRAS-mutated and KRAS wildtype patients [41]. CDKN2A/B loss might have negative prognostic and predictive value for lung cancer with immunotherapy, as reported by others as well [42]. It was reported that cell cycle, SHP2, MYC, and mTOR were among the key pathways for cell fitness by CRISPR/Cas 9 knockout screening with the KRAS G12C inhibitor MRTX849, and the combination of the KRAS G12C inhibitor with the CDK4/6 inhibitor palbociclib demonstrated more tumor regression in xenograft tumor models than either single agent alone [6]. The genomic alteration of CDKN2A/B could be a predictive marker for the combination therapy of the KRAS inhibitor and the CDK 4/6 inhibitor in selected patients [6].

KRAS comutation with MET genomic alterations also resulted in a shorter median OS (3.4 vs. 17 months, HR = 3.80 (1.44–10.05), \( p < 0.01 \), Figure 3C). The MET receptor tyrosine kinase (RTK) and its ligand hepatocyte growth factor (HGF) play an important role in cancer development as well as in innate and acquired resistance to lung cancer treatment, including EGFR inhibition [43]. It has been well documented that MET genomic alterations were associated with worse outcomes of lung cancer immunotherapy [44,45]. MET bidirectionally regulates both cancer cells and different immune cells, and MET expression in monocytes/macrocytes/neutrophils was associated with IL-10 expression and immunosuppressive myeloid cells [46–49]. The crosstalk of the MET and KRAS pathways could confer resistance to lung cancer-targeted therapies [50,51]. KRAS amplification contributes to the resistance to MET inhibition in lung cancer, and MET amplification was noticed in the acquired resistance to the KRAS G12C inhibitor [29,51]. The combination strategies of KRAS and MET targeting as well as immunotherapy warrant more investigation.

Consistent with previous findings in lung cancer, KRAS\(^{G12C} \) (32/87, 36.8%) was the most common mutation subtype in our study population, followed by G12V (19/87, 21.9%), G12D (18/87, 20.7%), G12A (6/87, 6.9%), and other mutations (Table 2, Figure 1 and [52]). There was more progression of the disease than the response in KRAS\(^{G12D} \)-mutated patients (Table 2, OR (95% CI) = 0.31 (0.09–0.95), \( p = 0.048 \)); however, the association of a better OS with KRAS G12D mutation was revealed in the multivariate analysis, which indicated that KRAS G12D-mutated patients, especially those who had responses with immunotherapy, had a longer OS compared with patients who had other KRAS mutations (Table 3, HR (95% CI) = 0.09 (0.01–0.68), \( p = 0.02 \)). KRAS\(^{G12V} \) mutations had a trend toward a worse OS but were not statistically significant (Tables 2 and 3). Due to the limited sample size, our study included only one patient with a KRAS\(^{Q61L} \) mutation, who had progression of the disease.
The samples sizes were also not sufficient to detect the statistical significance in other KRAS mutation subtypes, such as other uncommon codon 12, codon 13, and codon 61 mutations. There was heterogeneity in the prognostic and predictive roles of KRAS mutation subtypes with immunotherapy. Each KRAS mutation subtype has its unique biochemical and clinicopathological features, and the differences between the mutation subtypes in cancer and treatment are not fully understood yet [53–56]. The KRAS\textsuperscript{G12D} mutant has an intrinsic wild-type and SOS1 guanine exchange activities, while KRAS\textsuperscript{G61} mutants were defected in GTP hydrolysis [55,57]. In another study of 144 KRAS-mutated non-squamous NSCLC patients, patients who had KRAS\textsuperscript{G12C} or other KRAS mutations had no significant difference in clinical features, treatment, and survival [58]. In a study with 218 KRAS-mutated Japanese patients treated with ICIs after first-line chemotherapy, KRAS\textsuperscript{G12C} was significantly associated with high TMB (≥10 mut/Mb), and KRAS\textsuperscript{G12C} or KRAS\textsuperscript{G12V} were associated with high PD-L1 expression (≥50%). The median progression-free survival (mPFS) was significantly longer in patients with KRAS G12C or G12V than it was in other KRAS mutations [59]. In total, 15% of the patients had STK11 mutations without a difference in the comutation frequency among the different KRAS mutation subtypes, and the mPFS was significantly shorter with STK11 comutations with KRAS G12C or G12V (1.8 vs. 5.7 months, HR 1.97 (95% CI 1.06–3.41), p = 0.02) [59]. In another cohort of 1194 patients with KRAS-mutated NSCLC treated at the Memorial Sloan Kettering Cancer Center, KRAS\textsuperscript{G12C} and other KRAS mutations (15% G12D, 16% G12V, 8% G12A, 4% G13D) had similar comutation patterns and outcomes with similar response rates between patients with KRAS\textsuperscript{G12C} or other KRAS mutations in patients with PD-L1 higher than 50% (n = 103, 40% vs. 58%, p = 0.06) [60]. While most of the previously published data were comparing G12C and non-G12C mutations, our findings on the association of G12D mutations with immunotherapy outcomes indicated further investigation into all allele-specific alterations or KRAS amplifications and their association with immunotherapy outcomes.

5. Conclusions

The associations of responses and OS with KRAS mutation subtypes and comutations were analyzed in 87 KRAS-mutated lung cancer patients treated with ICIs. We found that the comutation of MET and CDKN2A/B loss was associated with a worse OS. The limitations of this study are that it is a single-institution retrospective study with a limited sample size, and no correlative tissue and blood samples were included in this project. Our findings of different outcomes of KRAS G12D, G12V, and Q61L with immunotherapy warrant independent and larger population validation.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14194933/s1, Table S1: Overall Survival and Associations with KRAS Co-mutations.

Author Contributions: R.S. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. D.Z., H.L., I.M. and R.S. contributed substantially to the study concept and design. D.Z., H.L., I.M., T.M., C.C., J.F., P.K., V.V., L.A., S.H., M.A., R.P., B.A., L.E., E.M., M.S., A.A. and R.S. made substantial contributions to the acquisition, analysis, or interpretation of the data for the manuscript. D.Z., H.L., I.M., M.S., A.A. and R.S. contributed substantially to the drafting of the manuscript. T.M., C.C., J.F., P.K., V.V., L.A., S.H., M.A., R.P., B.A., L.E., E.M. and R.S. contributed to the critical revision of the manuscript for important intellectual content, the final approval of the version to be published, and the agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by the National Cancer Institute, National Institutes of Health (Grant P30CA033572).
Institutional Review Board Statement: The study was approved by the COH Institutional Review Board (IRB #18529) and the Department of Health and Human Services. The study was conducted according to the standards of Good Clinical Practice, the Declaration of Helsinki, and the US Department of Health and Human Services.

Informed Consent Statement: Informed consent was waived, as per IRB requirements for retrospective studies on clinical and molecular information.

Data Availability Statement: The data presented in this study are available in the supplementary files.

Acknowledgments: We would like to thank the City of Hope clinical staff for their dedication to taking care of patients.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Johnson, M.L.; Sima, C.S.; Chaft, J.; Paik, P.K.; Pao, W.; Kris, M.G.; Ladanyi, M.; Riely, G.J. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer 2013, 119, 356–362. [CrossRef]
2. Slebos, R.J.; Kibbelaar, R.E.; Dalesio, O.; Kooistra, A.; Stam, J.; Meijer, C.J.; Wagenaar, S.S.; Vanderschueren, R.G.; van Zandwijk, N.; Mooi, W.J.; et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med. 1990, 323, 561–565. [CrossRef]
3. Ostrem, J.M.; Peters, U.; Sos, M.L.; Wells, J.A.; Shokat, K.M. KRAS(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503, 548–551. [CrossRef] [PubMed]
4. Stalnecker, C.A.; Der, C.J. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers. Cancer Discov. 2012, 2, 147–153. [CrossRef] [PubMed]
5. Canon, J.; Rex, K.; Saiki, A.Y.; Mohr, C.; Cooke, K.; Bagal, D.; Gaida, K.; Holt, T.; Knutson, C.G.; Koppara, N.; et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 2019, 575, 217–223. [CrossRef]
6. Hallin, J.; Engstrom, L.D.; Hargis, L.; Calinisan, A.; Aranda, R.; Briere, D.M.; Sudhakar, N.; Bowcut, V.; Baer, B.R.; Ballard, J.A.; et al. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov. 2020, 10, 54–71. [CrossRef] [PubMed]
7. Govindan, R.; Fakih, M.; Price, T.; Falchook, G.; Desai, J.; Kuo, J.; Strickler, J.; Krauss, J.; Li, B.; Denlinger, C.; et al. Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours. Ann. Oncol. 2019, 30, v159–v193. [CrossRef] [PubMed]
8. Hong, D.S.; Fakih, M.G.; Strickler, J.H.; Desai, J.; Durn, G.A.; Shapiro, G.I.; Falchook, G.S.; Price, T.J.; Sacher, A.; Denlinger, C.S.; et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N. Engl. J. Med. 2020, 383, 1207–1217. [CrossRef]
9. Ou, S.I.; Jänne, P.A.; Leal, T.A.; Rybkin, I.I.; Sabari, J.K.; Barve, M.A.; Bazhenova, L.; Johnson, M.L.; Velastegui, K.L.; Cilliers, C.; et al. First-In-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients with Advanced KRASG12C Solid Tumors (KRYS1-1). J Clin Oncol 2022, jco2102752. [CrossRef] [PubMed]
10. Salgia, R.; Pharaoh, R.; Mambetsariev, I.; Nam, A.; Sattler, M. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell. Rep. Med. 2021, 2, 100186. [CrossRef]
11. Jänne, P.A.; Riely, G.J.; Gadgeel, S.M.; Heist, R.S.; Ou, S.I.; Fachecho, J.M.; Johnson, M.L.; Sabari, J.K.; Leventakos, K.; Yau, E.; et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N. Engl. J. Med. 2022, 387, 120–131. [CrossRef]
12. Skoulidis, F.; Li, B.T.; Dy, G.K.; Price, T.J.; Falchook, G.S.; Wolf, J.; Italiano, A.; Schuler, M.; Borghaei, H.; Barlesi, F.; et al. Sotorasib for Lung Cancers with KRASG12C Mutation. N. Engl. J. Med. 2021, 384, 2371–2381. [CrossRef] [PubMed]
13. Lapinski, P.E.; King, P.D. Regulation of Ras signal transduction during T cell development and activation. Ann. J. Clin. Exp. Immunol. 2012, 1, 147–153.
14. Briere, D.M.; Li, S.; Calinisan, A.; Sudhakar, N.; Aranda, V.; Hargis, L.; Peng, D.H.; Deng, J.; Engstrom, L.D.; Hallin, J.; et al. The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. Mol. Cancer Ther. 2021, 20, 975–985. [CrossRef]
15. Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; et al. Nivolumab versus Docetaxel in Advanced Non-Squamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 373, 1627–1639. [CrossRef] [PubMed]
16. Brahmer, J.R.; Govindan, R.; Anders, R.A.; Antonia, S.J.; Sagorsky, S.; Davies, M.J.; Dubinett, S.M.; Ferris, A.; Gandhi, L.; Garon, E.B.; et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J. Immunother. Cancer 2018, 6, 75. [CrossRef]
17. Gandhi, L.; Rodriguez-Areú, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M.J.; Powell, S.F.; et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 378, 2078–2092. [CrossRef] [PubMed]
18. Horn, L.; Mansfield, A.S.; Szczesna, A.; Havel, L.; Krazowski, M.; Hochmair, M.J.; Huemer, F.; Losonczy, G.; Johnson, M.L.; Nishio, M.; et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 379, 2220–2229. [CrossRef] [PubMed]
19. Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gumus, M.; Mazieres, J.; Hermes, B.; Cay Senler, F.; Csosz, T.; Fulop, A.; et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* 2018, 379, 2040–2051. [CrossRef]

20. Antonia, S.J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Yokoi, T.; Chiappori, A.; Lee, K.H.; de Wit, M.; et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* 2017, 377, 1919–1929. [CrossRef] [PubMed]

21. Forde, P.M.; Chaft, J.E.; Smith, K.N.; Anagnostou, V.; Cottrell, T.R.; Hellmann, M.D.; Zahurak, M.; Yang, S.C.; Jones, D.R.; Broderick, S.; et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. *New Engl. J. Med.* 2018, 378, 1976–1986. [CrossRef] [PubMed]

22. Wang, D.Y.; Salem, J.E.; Cohen, J.V.; Chandra, S.; Menzer, C.; Ye, F.; Zhao, S.; Das, S.; Beckermann, K.E.; Ha, L.; et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. *JAMA Oncol.* 2018, 4, 1721–1728. [CrossRef] [PubMed]

23. Borghaei, H.; Langer, C.J.; Gadgeel, S.; Papadimitrakopoulou, V.A.; Patnaik, A.; Powell, S.F.; Gentzler, R.D.; Martins, R.G.; Stevenson, J.P.; Jalal, S.I.; et al. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. *J. Thorac. Oncol.* Off. Publ. Int. Assoc. Study Lung Cancer 2018, 14, 124–129. [CrossRef] [PubMed]

24. Kalvala, A.; Wallet, P.; Yang, L.; Wang, C.; Li, H.; Nam, A.; Nathan, A.; Mambetsariev, I.; Poroyko, V.; Gao, H.; et al. Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. *J. Clin. Med.* 2019, 8, 1726. [CrossRef] [PubMed]

25. Galan-Cobo, A.; Sithideatphaiboon, P.; Qu, X.; Poteete, A.; Pisegna, M.A.; Tong, P.; Chen, P.H.; Broughs, L.K.; Rodriguez, M.M.; Zhang, W.; et al. LBK1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. *Cancer Res.* 2019, 79, 3251–3267. [CrossRef] [PubMed]

26. Romero, R.; Sayin, VI.; Davidson, S.M.; Bauer, M.R.; Singh, S.X.; LeBoeuf, S.E.; Karakousi, T.R.; Ellis, D.C.; Bhutkar, A.; Sánchez-Rivera, F.J.; et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. *Nat. Med.* 2017, 23, 1362–1368. [CrossRef]

27. Best, S.A.; Ding, S.; Kersbergen, A.; Dong, X.; Song, J.Y.; Xie, Y.; Reljic, B.; Li, K.; Vince, J.E.; Rathi, V.; et al. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. *Nat. Commun.* 2019, 10, 4190. [CrossRef]

28. Suzuki, S.; Yonesaka, K.; Teramura, T.; Takehara, T.; Kato, R.; Sakai, H.; Haratani, K.; Tanizaki, J.; Kawakami, H.; Hayashi, H.; et al. KRAS Inhibitor Resistance in MET-Amplified KRAS (G12C) Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms. *Clin. Cancer Res.* 2021, 27, 5697–5707. [CrossRef]

29. Awad, M.M.; Liu, S.; Rybkin, I.I.; Arbour, K.C.; Dilly, J.; Zhu, V.W.; Johnson, M.L.; Heist, R.S.; Patil, T.; Riely, G.J.; et al. Acquired Resistance to KRAS(G12C) Inhibition in Cancer. *N. Engl. J. Med.* 2021, 384, 2382–2393. [CrossRef]

30. Jeanson, A.; Tomasini, P.; Souquet-Bressand, M.; Brandone, N.; Boucekine, M.; Grangeon, M.; Chaleat, S.; Khobta, N.; Milia, J.; Mhanna, L.; et al. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). *J. Thorac. Oncol.* Off. Publ. Int. Assoc. Study Lung Cancer 2019, 14, 1095–1101. [CrossRef]

31. Liu, C.; Zheng, S.; Jin, R.; Wang, X.; Wang, F.; Zang, R.; Xu, H.; Lu, Z.; Huang, J.; Lei, Y.; et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. *Cancer Lett.* 2020, 470, 95–105. [CrossRef] [PubMed]

32. Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J.L.; Rekhtman, N.; et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients with Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. *J. Clin. Oncol.* 2018, 36, 633–641. [CrossRef]

33. Biton, J.; Mansuet-Lupo, A.; Pecuchet, N.; Alifano, M.; Ouakrim, H.; Arroudeau, J.; Boudou-Rouquette, P.; Goldwasser, F.; Leroy, K.; Goc, J.; et al. TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. *Cancer Discov.* 2018, 24, 5710–5723. [CrossRef] [PubMed]

34. Dong, Z.Y.; Zhong, W.Z.; Zhang, X.C.; Su, J.; Xie, Z.; Liu, S.Y.; Hu, Y.; Chen, H.J.; Sun, Y.L.; Zhou, Q.; et al. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. *Clin. Cancer Res.* 2017, 23, 3012–3024. [CrossRef]

35. Blons, H.; Garinet, S.; Laurent-Puig, P.; Oudart, J.B. Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. *J. Thorac. Dis.* 2019, 11, S25–S36. [CrossRef]

36. Amann, I.; Mambetsariev, I.; Gupta, R.; Achuthan, S.; Wang, Y.; Pharaon, R.; Massarelli, E.; Koczynwas, M.; Reckamp, K.; Salgia, R. Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. *J. Thorac. Dis.* 2019, 11, S25–S36. [CrossRef]

37. Skoulidis, F.; Byers, L.A.; Diao, L.; Papadimitrakopoulou, V.A.; Tong, P.; Izzo, J.; Behrens, C.; Kadara, H.; Parra, E.R.; Canales, J.R.; et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. *Cancer Discov.* 2015, 5, 860–877. [CrossRef]

38. Skoulidis, F.; Goldberg, M.E.; Greenawalt, D.M.; Hellmann, M.D.; Awad, M.M.; Gainor, J.F.; Schrock, A.B.; Hartmaier, R.J.; Trabucco, S.E.; Gay, L.; et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. *Cancer Discov.* 2018, 8, 822–835. [CrossRef]
39. Arbour, K.C.; Jordan, E.; Kim, H.R.; Dienstag, J.; Yu, H.A.; Sanchez-Vega, F.; Lito, P.; Berger, M.; Solit, D.B.; Hellmann, M.; et al. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. *Clin. Cancer Res.* 2018, 24, 334–340. [CrossRef]

40. Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur. J. Cancer* 2009, 45, 228–247. [CrossRef]

41. Zhao, D.; Mambetsariev, I.; Fricke, J.; Fann, P.; Kulkarni, P.; Xing, Y.; Lee, P.P.; et al. Association of MET loss-of-function with immunocheckpoint resistance in non-small cell lung cancer. *Sci. Rep.* 2021, 11, 20059. [PubMed]

42. Gutiontov, S.I.; Turchan, W.T.; Spurr, L.F.; Rouhani, S.J.; Chervin, C.S.; Steinhardt, G.; Lager, A.M.; Wanjari, P.; Malik, R.; Connell, J.; et al. Periostin in Non-Small-Cell Lung Cancer: Clinico-pathological Features, Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer. *Clin. Cancer Res.* 2020, 26, 8188–8199. [CrossRef] [PubMed]

43. Salgia, R. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. *Mol. Cancer Ther.* 2017, 16, 555–565. [CrossRef] [PubMed]

44. Mazieres, J.; Drilon, A.; Lusque, A.; Mhanna, L.; Cortot, A.B.; Mezquita, L.; Thai, A.A.; Mascaux, C.; Couraud, S.; Veillon, R.; et al. MET is required for the recruitment of anti-tumoural neutrophils. *Nature* 2015, 521, 349–353. [CrossRef]

45. Hunter, J.C.; Manandhar, A.; Carrasco, M.A.; Gurbani, D.; Gondi, S.; Westover, K.D. Biochemical and Structural Analysis of Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. *Clin. Cancer Res.* 2019, 25, 4965–4976. [CrossRef] [PubMed]

46. Hobbs, G.A.; Der, C.J. RAS Mutations Are Not Created Equal. *Clin. Cancer Res.* 2018, 24, 3035–3045. [CrossRef] [PubMed]

47. Ricciuti, B.; Son, J.; Okoro, J.J.; Mira, A.; Patrucco, E.; Eum, Y.; Wang, X.; Paranal, R.; Wang, H.; Lin, M.; et al. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. *Clin. Cancer Res.* 2022, 28, 1640–1650. [CrossRef]

48. Titmarsh, H.F.; O’Connor, R.; Dhillon, K.; Akram, A.R. The Emerging Role of the c-MET-HGF Axis in Non-small Lung Cancer Tumor Immunology and Immunotherapy. *Front. Oncol.* 2020, 10, 54. [CrossRef]

49. Papaccio, F.; Della Corte, C.M.; Viscardi, G.; Di Liello, R.; Esposito, G.; Sparano, F.; Ciardiello, F.; Morgillo, F. HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. *Int. J. Mol. Sci.* 2018, 19, 3595. [CrossRef]

50. Lu, D.; Nagelberg, A.; Chow, J.L.; Chen, Y.T.; Michalchuk, Q.; Somwar, R.; Lockwood, W.W. MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis. *Cancers* 2022, 14, 1378. [CrossRef]

51. Bahcall, M.; Awad, M.M.; Sholl, L.M.; Wilson, F.H.; Xu, M.; Wang, S.; Palakurthi, S.; Choi, J.; Ivanova, E.V.; Leonardi, G.C.; et al. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small-Cell Lung Cancer. *Clin. Cancer Res.* 2018, 24, 5963–5976. [CrossRef] [PubMed]

52. Wood, K.; Hensing, T.; Malik, R.; Salgia, R. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer. A Review. *JAMA Oncol.* 2016, 2, 805–812. [CrossRef] [PubMed]

53. Johnson, C.; Burkhart, D.L.; Haigis, K.M. Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention. *Cancer Discov.* 2022, 12, 913–923. [CrossRef] [PubMed]

54. Hunter, J.C.; Manandhar, A.; Carrasco, M.A.; Gurbani, D.; Gondi, S.; Westover, K.D. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. *Mol. Cancer. Res.* 2015, 13, 1325–1335. [CrossRef] [PubMed]

55. Hobbs, G.A.; Der, C.J. RAS Mutations Are Not Created Equal. *Cancer Discov.* 2019, 9, 696–698. [CrossRef]

56. Ricciuti, B.; Son, J.; Okoro, J.J.; Mira, A.; Patrucco, E.; Eum, Y.; Wang, X.; Paranal, R.; Wang, H.; Lin, M.; et al. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. *Clin. Cancer Res.* 2022, 28, 1640–1650. [CrossRef]

57. Kobayashi, Y.; Chhoue, C.; Li, J.; Price, K.S.; Kiedrowski, L.A.; Hutchins, J.L.; Hardin, A.I.; Wei, Z.; Hong, F.; Bahcall, M.; et al. Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. *Nature* 2022, 603, 335–342. [CrossRef]

58. Cui, W.; Franchini, F.; Alexander, M.; Officer, A.; Wong, H.L.; Izerman, M.J.; Desai, J.; Solomom, B.J. Assessing the significance of KRAS G12C mutation: Clinical pathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort. *J. Clin. Oncol.* 2020, 38, e19324. [CrossRef]

59. Tamiya, Y.; Zenke, Y.; Matsumoto, S.; Furuya, N.; Sakamoto, T.; Kato, T.; Nishino, K.; Shingyoji, M.; Miyamoto, S.; Shirakawa, C.; et al. Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS–mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan). *J. Clin. Oncol.* 2020, 38, 9589. [CrossRef]

60. Arbour, K.C.; Rizvi, H.; Plodkowski, A.J.; Hellmann, M.D.; Knezevic, A.; Heller, G.; Yu, H.A.; Ladanyi, M.; Kris, M.G.; Arcila, M.E.; et al. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer. *Clin. Cancer Res.* 2021, 27, 2209–2215. [CrossRef]